Voxilaprevir (GS-9857) 是一种含氟大环丙型肝炎病毒 (HCV) 非结构蛋白 (NS) 3/4A 蛋白酶抑制剂。对基因型 1-6 HCV 具有很强的体外抗病毒活性，并广泛覆盖 NS3/4A 蛋白酶多态性。GS-9857 提高了对常见的 NS3 抗药性相关突变体 (RAVs) 的覆盖率。
| Cas No. | 1535212-07-7 |
| 别名 | 伏西瑞韦; GS-9857 |
| Canonical SMILES | O=C([C@H]1N(C([C@@H](NC(O[C@H]2[C@H]3C2)=O)C(C)(C)C)=O)C[C@@](OC4=NC5=CC(OC)=CC=C5N=C4C(F)(CCCC3)F)([H])[C@H]1CC)N[C@]6([C@H](C(F)F)C6)C(NS(=O)(C7(CC7)C)=O)=O |
| 分子式 | C40H52F4N6O9S |
| 分子量 | 868.93 |
| 溶解度 | Soluble in DMSO |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Voxilaprevir (GS-9857) is a fluorinated macrocyclic hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor with potent in vitro antiviral activity against genotypes 1-6 HCV and broad coverage of NS3/4A protease polymorphisms. GS-9857 improves coverage against commonly encountered NS3 resistance-associated variants (RAVs)[1][2].
Hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease[1] [1]. Rodriguez-Torres M, et al. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat. 2016 Aug;23(8):614-22.
[2]. Lawitz E, et al. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C VirusInfection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 Nov;151(5):893-901.e1. |
